Contact the Editorial Desk

Editorial correspondence

Carolina Peptide reads correspondence on the research record: a citation quoted inaccurately, a newly published study on GLOW's constituents, KPV, or TB-500, or a regulatory or WADA-status update that changes how a finding should be framed. This is the most useful class of message this desk receives, and each one is checked before any change is made to the site.

The most actionable messages specify the page, the exact passage in question, and a supporting reference — a DOI or PubMed identifier where possible — so the proposed correction can be verified against its source.

Editorial mailbox: editors@carolinapeptide.com

What this desk cannot do

Carolina Peptide is a literature digest, not a clinical service. It cannot advise on or recommend human use of GLOW, KPV, TB-500, or any related compound; suggest a dose or schedule for any individual; evaluate whether a cited animal or preclinical finding applies to a specific person; or help source, sell, or locate any compound from any supplier. Because TB-500 (and, by extension, GLOW) sits on WADA's Prohibited List, this desk also cannot advise athletes on sport-eligibility questions beyond stating the compound's prohibited status. None of the compounds discussed is FDA-approved. Readers seeking medical guidance should consult a licensed clinician in their own jurisdiction. Responses to editorial correspondence are not guaranteed and this mailbox is monitored intermittently.